FACULTY
William A. Fischer II, MD
Associate Professor of Medicine, Pulmonary and Critical Care Medicine
Director of Emerging Pathogens
Institute for Global Health and Infectious Diseases
The University of North Carolina
Chapel Hill, NC
PROGRAM OVERVIEW
This activity discusses the care of patients hospitalized with SARS-CoV-2 infection. The program will address the burden of COVID-19 in the US as well as the currently circulating strains. The program is designed to help clinicians integrate the latest treatment guidelines and management strategies for this patient population into their practice. The program will present the results of the latest clinical trials of novel therapies for COVID 19 to inform clinicians’ choice of therapy for patients hospitalized with SARS-CoV-2 to reduce the risk of mortality.
TARGET AUDIENCE
This activity is designed to meet the educational needs of intensive care physicians, pulmonologists, rheumatologists, infectious disease specialists, emergency physicians, hospitalists, pharmacists, nurses, nurse practitioners, physician assistants, and other members of the multidisciplinary team to ensure optimal patient outcomes in the inpatient management of COVID-19 infection.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Evaluate the burden of COVID-19 in the United States and the need to use therapies to reduce mortality risk in hospitalized patients
- Integrate the latest treatment guidelines and appropriate strategies into the management of hospitalized patients with SARS-CoV-2 infection
- Analyze the results of the latest clinical trials concerning the use of novel therapies to reduce the risk of mortality in patients hospitalized as a result of COVID-19
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with SARS-CoV-2 infection.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education for RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
| William A. Fischer II, MD | Dr. Fischer discloses that he has been contracted for COVID-19 research for Ridgeback Biopharmaceuticals and has worked as a consultant for Merck and Roche. He also worked for Syneos Health and Janssen for adjudication of adverse events in respiratory syncytial virus (RSV) and influenza studies, respectively, and served as the site principal investigator for the Phase 1 Lilly study of bamlanivimab and for the Phase 2 study of casirivimab/imdevimab at the University of North Carolina. |
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Alexandra Kadner, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
- Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Morgan Kravarik, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 1, 2022
EXPIRATION DATE: November 1, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
